Dec 7 (Reuters) - ProMetic Life Sciences Inc PLI.TO :
* Announced new data from plasma-derived plasminogen replacement therapy phase
i clinical trial for the treatment of cpd
* There were no plasminogen antibodies detected and the results confirm the
established therapeutic dose of 6 mg/kg
* Says safety and tolerability confirmed by phase i trial results
* Says anticipate starting the enrollment of patients in the phase ii/iii trial
during the first quarter of 2016
* FDA has agreed to accelerated regulatory approval pathway, given "rarity of
condition and the related unmet medical need"
* Source text for Eikon
* Further company coverage PLI.TO